- Human Biospecimens
- Biospecimen Contributors
LEXINGTON, Mass., Nov. 4, 2021 /PRNewswire/ — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online marketplace for human biospecimens, today reported its financial results for the three and nine-month periods ended September 30, 2021.
“In the third quarter of 2021, we continued to achieve strong growth in our core biospecimen business, while simultaneously expanding our market penetration through increased sales and marketing initiatives,” said Christopher Ianelli, MD, PhD, CEO and President of iSpecimen. “These efforts contributed to nine-month 2021 revenue results that have already surpassed our full-year revenue for 2020. At the same time, we increased our number of supplier organizations under agreement to nearly 200 while growing our registered users on the iSpecimen Marketplace.”
Dr. Ianelli added, “iSpecimen continues to execute its strategic initiatives to broaden our service offerings and expand our number of supplier organizations under agreement to grow our procurement reach and data assets. At the same time, we are assessing potential investments that can further enhance our technology and expand our capabilities. We believe these efforts will allow us to increase our value proposition for users and suppliers, increase our sales momentum and drive long-term revenue growth and shareholder value.”
Q3 2021 Financial & Operational Highlights
Recent Corporate Updates
Financial Results for the Third Quarter of 2021
Revenue for the third quarter of 2021 increased 21% to $2.7 million, compared to approximately $2.3 million for the same period in 2020. This increase was primarily driven by the success of its maturing sales team, continued demand for specimens from patients with known COVID-19 test results, and an increasing demand for specimens in non-COVID-19 research areas. For the third quarter of 2021, COVID-19 related revenue accounted for approximately 34% of total revenue, compared to 63% for the third quarter of 2020. COVID-19 related revenue is expected to continue to decline, while being replaced by increased demand for specimens in non-COVID-19 research areas.
Cost of revenue was $0.9 million for the third quarter of 2021, consistent with the prior year. This was attributable to a 14% increase in the average cost per specimen impacted by the specimen mix, offset by a decrease of 12% in the number of specimens accessioned for the current period compared to the same period in 2020.
General and administrative expenses were $1.7 million for the third quarter of 2021, compared to $0.8 million for the third quarter of 2020. The year-over-year increase was primarily attributable to an increase in costs related to iSpecimen becoming a public company in the second quarter of this year, including increases in legal and accounting expenses, an increase in other general and administrative expenses related to amortization of internally developed software, associated software licenses, human resource related expenses, insurance costs and facility expenses, an increase in director and officer insurance, and an increase in payroll-related costs.
Net loss was approximately $1.1 million for the third quarter of 2021, compared to net loss of over $1.2 million for the same period in 2020.
Cash was approximately $9.8 million as of September 30, 2021.
Conference Call and Webcast Information
The Company will host a conference call and audio webcast today, Thursday, November 4th at 8:30 a.m. Eastern Time featuring remarks by Christopher Ianelli, MD, PhD, CEO and President, Tracy Curley, CFO, and Jill Mullan, COO.
iSpecimen Third Quarter 2021 Results Conference Call
Thursday, November 4, 2021
8:30 a.m. Eastern Time
+1-855-327-6838 (Toll Free) or + 1-604-235-2082 (International)
For interested individuals unable to join the conference call, a replay will be available through November 18, 2021, at +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 10016869. An archived version of the webcast will also be available on iSpecimen’s Investor Relations site: https://ispecimen.irpass.com/.
iSpecimen offers an online marketplace for human biospecimens, connecting life scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. For more information about iSpecimen, please visit www.ispecimen.com.
Forward Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as “may,” “will,” “expect,” “intend,” “anticipate,” believe,” “estimate” and “continue” or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.
Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risks factors contained in the Company’s filings with the Securities and Exchange Commission, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company’s forward-looking statements occurs, the Company’s business, financial condition and operating results may vary materially from those expressed in the Company’s forward-looking statements.
Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
KCSA Strategic Communications
Allison Soss / Scott Eckstein
|CONDENSED BALANCE SHEETS|
September 30, 2021
December 31, 2020
|Cash||$ 9,790,732||$ 695,909|
|Accounts receivable – unbilled||1,750,744||652,761|
|Accounts receivable, net of allowance for doubtful accounts of $141,952 and $108,096 at September 30, 2021 and December 31, 2020, respectively||2,718,682||1,526,392|
|Prepaid expenses and other current assets||459,321||417,929|
|Tax credit receivable, current portion|| 179,376
|Total current assets||14,898,855||3,472,367|
|Property and equipment, net||44,749||75,589|
|Internally developed software, net||2,650,867||2,634,139|
|Tax credit receivable, net of current portion||–||–|
|Security deposits|| 27,601
|Total assets||$ 17,622,072
|Accounts payable||$ 351,424||$ 1,792,432|
|Convertible notes payable, related parties, net of unamortized debt discount and debt issuance costs||–||5,490,811|
|Derivative liability for embedded conversion features on convertible notes payable||–||2,373,000|
|Bridge notes payable, net of debt issuance costs||–||4,589,228|
|Bridge notes payable, related parties||–||1,905,000|
|Note payable, current portion||–||604,109|
|Deferred revenue|| 718,723
|Total current liabilities||2,102,793||22,135,688|
|Note payable, net of current portion||–||178,899|
|Term loan|| 3,428,380
|Total liabilities|| 5,531,173
|Commitments and contingencies|
|Series B convertible preferred stock, $0.0001 par value, 3,200,000 shares authorized, 0 and 572,465 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively||–||7,999,997|
|Series A-1 convertible preferred stock, $0.0001 par value, 556,550 shares authorized, 0 and 100,365 issued and outstanding at September 30, 2021 and December 31, 2020, respectively||–||561,041|
|Series A convertible preferred stock, $0.0001 par value, 3,427,871 shares authorized, 0 and 618,182 issued and outstanding at September 30, 2021 and December 31, 2020, respectively|| –
|Total convertible preferred stock|| –
|Stockholders’ equity (deficit)|
|Common stock, $0.0001 par value, 200,000,000 shares authorized, 6,996,758 issued, and 6,965,758 outstanding at September 30, 2021, and 16,000,000 shares authorized, 967,213 issued and 936,213 outstanding at December 31, 2020||697||94|
|Additional paid-in capital||48,059,389||1,779,698|
|Treasury stock, 31,000 shares at September 30, 2021 and December 31, 2020, at cost||(172)||(172)|
|Accumulated deficit|| (35,969,015)
|Total stockholders’ equity (deficit)|| 12,090,899
|Total liabilities, convertible preferred stock and stockholders’ equity (deficit)||$ 17,622,072
|CONDENSED STATEMENTS OF OPERATIONS|
|Three months ended September 30,||Nine months ended September 30,|
|Cost of revenue||913,833||903,862||4,026,680||2,032,111|
|Sales and marketing||513,107||506,641||1,690,085||1,305,897|
|General and administrative|| 1,636,346
|Total operating expenses|| 4,177,607
|Loss from operations|| (1,459,073)
|Other expense, net|
|Change in fair value of derivative liability on convertible notes||–||(54,000)||(271,000)||(76,000)|
|Change in fair value of derivative liability on bridge notes and bridge notes, related parties||–||–||1,582,700||–|
|Gain (loss) on extinguishment of bridge notes and bridge notes, related parties||–||–||(2,740,425)||–|
|Loss on extinguishment of convertible notes and convertible notes, related parties||–||–||(260,185)||–|
|Gain on extinguishment of note payable||–||–||788,156||–|
|Other expense, net||(21,687)||–||(21,756)||6,691|
|Interest income|| 3,659
|Other expense, net|| (93,950)
|Income (loss) before benefit from income taxes||(1,553,023)||(1,246,469)||(6,911,428)||(3,058,540)|
|Benefit from income taxes|| –
|Net income (loss)||$ (1,553,023)
|Net income (loss) per share|
|Basic and diluted||$ (0.22)
|Weighted average common shares outstanding|
|Basic and diluted|| 6,960,330